Analytik Jena Establishes Subsidiary in Thailand
News May 07, 2013
Analytik Jena AG has established a new subsidiary, Analytik Jena Far East (Thailand) Ltd., giving it a presence in the Southeast Asian market.
Analytik Jena AG is using this new company to bolster its activities in the Southeast Asian market, increase its regional service for the sales partners and customers operating there and expand its regional sales activities.
In future, the company wants to strengthen its core business of Analytical Instrumentation from Bangkok with its ninth foreign subsidiary.
"To be successful in growth markets, a local presence is essential. Our international network gives us access to the global markets that are important for our business. These also include Southeast Asia with Thailand," said Klaus Berka, CEO of Analytik Jena AG.
Berka continued, "The region has an economic structure with many growth sectors. We expect significant sales growth here in the next few years."
Analytik Jena AG has operated with an office in Bangkok since 2001, out of which it serves retailers and customers with an on-site team of experts.
The company wants to strengthen its presence in Southeast Asia with its own infrastructure and develop a sales network for the entire Southeast Asian market via the subsidiary in Bangkok.
The product portfolio with analytical instrumentation technology in particular is to be sold via Analytik Jena Far East (Thailand) Ltd., which is to be a regional competence center.
In individual product divisions, such as atomic absorption spectrometry (AAS), Analytik Jena already has market shares of up to 20.0% in selected Asian markets.
In the last financial year, 2011/2012, Analytik Jena achieved an increase in sales of 30.8% in Asia, its most important export market, generating sales of EUR 39.2 m.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.